TITLE

Combination study of Invirase and Norvir starting

PUB. DATE
June 1996
SOURCE
AIDS Patient Care & STDs;Jun96, Vol. 10 Issue 3, p187
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
Announces the clinical trial to be conducted by Hoffman-La Roche Inc. with Abbott Laboratories on the protease inhibitors Invirase in combination with Norvir and their effectiveness in the treatment of HIV/AIDS. Distinct mutation profile of Invirase.
ACCESSION #
9709124515

 

Related Articles

  • New & improved.  // Pharmaceutical Executive;Feb98, Vol. 18 Issue 2, p108 

    Reports that the US Food and Drug Administration has granted marketing clearance for Hoffman-La Roche's Fortovase (saquinavir), a soft gelatin formulation of the first available protease inhibitor. Indication of the drug.

  • saquinavir:. Huber, Jeffrey T.; Gillaspy, Mary L. // Encyclopedic Dictionary of AIDS-Related Terminology;2000, p195 

    An encyclopedia entry for saquinavir is presented. Saquinavir is the first protease inhibitor approved by the U.S. Food and Drug Administration. The drug was approved more quickly than any other new HIV drug at that time. Saquinavir is manufactured by Roche Laboratories, with the trade name...

  • Roche files saquinavir NDA.  // Drug Topics;9/18/95, Vol. 139 Issue 18, p8 

    Reports on Hoffman-LaRoche's submission of a new drug application for Invirase or saquinavir, a protease inhibitor used in the treatment of AIDS.

  • NDA for ritonavir.  // Drug Topics;2/5/96, Vol. 140 Issue 3, p28 

    Reports on the submission of a New Drug Application by Abbott Laboratories for the ritonavir protease inhibitor.

  • Protease inhibitor.  // Drug Topics;1/22/96, Vol. 140 Issue 2, p27 

    Cites Abbott Laboratories' development of the protease inhibitor, ritonavir, to treat HIV infection. Packaging; Availability of Roche's protease inhibitor, saquinavir (Invirase) in December 1995.

  • HIV/AIDs activists protest drug price hike. Carrillo, Karen Juanita // New York Amsterdam News;2/12/2004, Vol. 95 Issue 7, p4 

    The announced plans by the pharmaceutical company Abbott Laboratories Inc. to raise prices for its AIDS medicine have caused outrage among HIV/AIDS activists. In December, 2003 Abbott announced it plans to raise the price of Norvir, its famed protease inhibitor drug. Norvir, which is more...

  • Combo therapy.  // Drug Topics;5/20/96, Vol. 140 Issue 10, p20 

    Reports that Hoffman-La Roche and Abbott are conducting a clinical trial to assess the safety of concurrent therapy with the companies' drugs Invirase and Norvir for treatment of AIDS.

  • Improved formulation of AIDS drug granted approval.  // Drug Store News;12/8/97, Vol. 19 Issue 20, pCP4 

    Reports the marketing approval granted to Hoffmann-LaRoche Inc. for the improved soft gelatin formulation of its protease inhibitor Invirase (saquinavir mesylate). Features of the product and its effectivity; Availability of Invirase.

  • HIV breakthroughs. O'Connor, Jeremy // Financial World;8/12/96, Vol. 165 Issue 11, p16 

    Reports on the development of an anti-HIV drug known as protease inhibitors. Features of the drug; Impact on the level of HIV virus; Estimated amount of that the market for the drugs will grow within a year; Five companies that markets the drug.

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics